Suppr超能文献

人生长激素替代治疗期间生长激素缺乏成年人血红蛋白浓度的增加。

Increase in haemoglobin concentrations in growth hormone deficient adults during human recombinant growth hormone replacement therapy.

作者信息

Ten Have S M, van der Lely A J, Lamberts S W

机构信息

Department of Medicine, Erasmus University Rotterdam, The Netherlands.

出版信息

Clin Endocrinol (Oxf). 1997 Nov;47(5):565-70. doi: 10.1046/j.1365-2265.1997.3241124.x.

Abstract

OBJECTIVE

Recombinant human growth hormone is being used increasingly in the treatment of GH deficiency in adults. In addition to erythropoietin, insulin-like growth factor-I (IGF-I) has been demonstrated to stimulate hematopoiesis in animals, especially rodents. We have determined the effect of growth hormone (GH) administration on haematopoiesis.

PATIENTS AND DESIGN

Seventeen patients (10 males and 7 females; mean age 47 +/- 2 years; range 30-59) with biochemically proven adult-onset GH deficiency (GHD) were treated with human recombinant growth hormone (rhGH) as replacement therapy for more than 96 weeks in a dosage of 12.5 micrograms/kg/day (initial dosage during the first 4 weeks 6.25 micrograms/kg/day). The diagnosis of GHD had been confirmed using a standard arginine-infusion test (0.5 g/kg body weight). Blood samples were collected for safety and efficacy parameters before and during the GH treatment period.

MEASUREMENTS

Routine methods were used for the haematological and biochemical measurements. IGF-I concentrations were measured, using a commercial RIA kit.

RESULTS

From week 36 and onwards, we observed a significant increase in individual haemoglobin (Hb) concentrations, especially in the male patients. Mean Hb in the male patients before treatment amounted to 9.1 +/- 0.2 mmol/l (range 8.1-10.5) and increased by 0.93 +/- 0.2 mmol/l (P < 0.05) after 120 weeks of rhGH replacement therapy. The mean Hb concentration in female patients before treatment was 8.1 +/- 0.1 mmol/l and an increase of 0.32 +/- 0.1 mmol/l (P < 0.05) was observed after 120 weeks. For all 17 patients the mean increase in Hb after 120 weeks was 0.73 +/- 0.2 mmol/l (P < 0.05). IGF-I concentrations also increased during therapy from 86 +/- 9 pg/l to 253 +/- 26 pg/l within 24 weeks (P < 0.05). No significant changes in leucocyte or platelet counts were found.

CONCLUSIONS

Long-term replacement therapy with rhGH in patients with adult-onset GHD induces a significant increase in Hb concentrations, while serum leucocyte and platelet counts do not change.

摘要

目的

重组人生长激素在成人生长激素缺乏症的治疗中应用越来越广泛。除促红细胞生成素外,胰岛素样生长因子-I(IGF-I)已被证明可刺激动物尤其是啮齿动物的造血功能。我们已确定生长激素(GH)给药对造血功能的影响。

患者与设计

17例经生化证实为成人起病型生长激素缺乏症(GHD)的患者(10例男性和7例女性;平均年龄47±2岁;范围30 - 59岁),接受重组人生长激素(rhGH)作为替代疗法治疗超过96周,剂量为12.5微克/千克/天(最初4周的起始剂量为6.25微克/千克/天)。GHD的诊断已通过标准精氨酸输注试验(0.5克/千克体重)得到证实。在GH治疗期间前后采集血样以检测安全性和疗效参数。

测量

采用常规方法进行血液学和生化测量。使用商用放射免疫分析试剂盒测量IGF-I浓度。

结果

从第36周起,我们观察到个体血红蛋白(Hb)浓度显著增加,尤其是男性患者。男性患者治疗前的平均Hb为9.1±0.2毫摩尔/升(范围8.1 - 10.5),rhGH替代治疗120周后增加了0.93±0.2毫摩尔/升(P<0.05)。女性患者治疗前的平均Hb浓度为8.1±0.1毫摩尔/升,120周后观察到增加了0.32±0.1毫摩尔/升(P<0.05)。对于所有17例患者,120周后Hb的平均增加量为0.73±0.2毫摩尔/升(P<0.05)。治疗期间IGF-I浓度在24周内也从86±9皮克/升增加到253±26皮克/升(P<0.05)。未发现白细胞或血小板计数有显著变化。

结论

成人起病型GHD患者长期接受rhGH替代治疗可使Hb浓度显著增加,而血清白细胞和血小板计数不变。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验